Artwork

Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

AUDIO JOURNAL OF ONCOLOGY—First Line Atezolizumab Extends Life in Unfit Patients with Lung Cancer

7:01
 
Share
 

Manage episode 344937611 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were not fit enough to be recommended standard platinum doublet chemotherapy lived longer when treated with the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab than patients in a comparison group who received a single-agent chemotherapy regimen.

https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal/session/calendar/2022-09-12

Faced with the reality that a large unfit population of patients with non-small cell lung cancer cannot be recommended standard treatment (and who typically received single agent chemotherapy, or best supportive car) Siow Ming Lee, PhD FRCP, IPSOS Trial Chair, Professor of Medical Oncology and Consultant Medical Oncologist at University College London Hospital, told the Audio Journal of Oncology’s Peter Goodwin how they investigated the use of single-agent atezolizumab checkpoint inhibition immunotherapy in patients deliberately chosen for their low performance status who had no proven options for initial treatment.

  continue reading

51 episodes

Artwork
iconShare
 
Manage episode 344937611 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were not fit enough to be recommended standard platinum doublet chemotherapy lived longer when treated with the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab than patients in a comparison group who received a single-agent chemotherapy regimen.

https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal/session/calendar/2022-09-12

Faced with the reality that a large unfit population of patients with non-small cell lung cancer cannot be recommended standard treatment (and who typically received single agent chemotherapy, or best supportive car) Siow Ming Lee, PhD FRCP, IPSOS Trial Chair, Professor of Medical Oncology and Consultant Medical Oncologist at University College London Hospital, told the Audio Journal of Oncology’s Peter Goodwin how they investigated the use of single-agent atezolizumab checkpoint inhibition immunotherapy in patients deliberately chosen for their low performance status who had no proven options for initial treatment.

  continue reading

51 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play